Special Issue "Management of Cutaneous Squamous Cell Carcinoma Patients"

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 January 2022.

Special Issue Editor

Dr. Chrysalyne D. Schmults
E-Mail Website
Guest Editor
Brigham and Women's Department of Dermatology, Harvard Medical School, Boston, MA, USA
Interests: squamous cell carcinoma; basal cell carcinoma; cutaneous sarcoma; cutaneous field cancerization; actinic keratosis; actinic damage; skin cancer prognostics; skin cancer treatment; skin cancer economics

Special Issue Information

Dear Colleagues,

The field of squamous cell carcinoma management encompasses a spectrum of diseases ranging from precursor lesions and field cancerization, where prophylaxis can improve outcomes, to small tumors that are easily removed, to aggressive diseases requiring treatment beyond surgery. The approach to treatment is multifactorial and can be complex since many patients have underlying immune dysfunctions or other co-morbidities as the affected population is generally the elderly. Thus, there are many components that influence decisions regarding best care practices.

This Special Issue aims to explore all areas of treatment including:

  1. prophylaxis: definitions, spectrum, and management of field cancerization;
  2. diagnostic work-up, impact of tumors and nodal staging on prognosis and management;
  3. surgical management including NCCN guidelines for high risk and very high risk tumors;
  4. the role of adjuvant and neoadjuvant therapy, including emerging intratumoral therapy;
  5. surveillance exams and imaging for timely identification of recurrence;
  6. current immunotherapy systemic treatment options for diseases not amenable to cure with surgery and/or radiation;
  7. systemic options for organ transplant recipients.

Dr. Chrysalyne D. Schmults
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • squamous cell carcinoma
  • cutaneous field cancerization
  • actinic keratosis
  • actinic damage
  • skin cancer prognostics
  • skin cancer treatment
  • skin cancer economics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

Systematic Review
Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?
Curr. Oncol. 2021, 28(4), 2317-2325; https://doi.org/10.3390/curroncol28040213 - 23 Jun 2021
Cited by 20 | Viewed by 1042
Abstract
Background: Squamous cell carcinoma (SCC) is one of the most common cancers involving skin and oral mucosa. Although this condition’s gold-standard treatment is the surgical removal of the lesions, the physician must propose alternative treatments in some cases due to the patient’s [...] Read more.
Background: Squamous cell carcinoma (SCC) is one of the most common cancers involving skin and oral mucosa. Although this condition’s gold-standard treatment is the surgical removal of the lesions, the physician must propose alternative treatments in some cases due to the patient’s ineligibility for surgery. Among the available alternative therapies, local chemotherapy may represent an initial treatment in combination with radiotherapy or systemic chemotherapy due to the low frequency of side-effects and the lack of necessity for expensive devices. Methods: In this paper, we review all available literature in various databases (PubMed, Scopus-Embase, Web of Science), proposing local chemotherapy as a treatment for cutaneous and oral SCC. Exclusion criteria included ocular lesions (where topical treatments are common), non-English language, and non-human studies. Results: We included 14 studies in this review. The majority were case reports and case series describing the treatment of non-resectable localized SCC with either imiquimod or 5-fluorouracil. We also analyzed small studies proposing combination treatments. Almost all studies reported an excellent clinical outcome, with a low risk of relapses in time. Conclusions: Resection of the lesion remains the gold-standard treatment for SCC. When this approach is not feasible, local chemotherapy may represent a treatment alternative, and it may also be associated with radiotherapy or systemic chemotherapy. Full article
(This article belongs to the Special Issue Management of Cutaneous Squamous Cell Carcinoma Patients)
Show Figures

Figure 1

Back to TopTop